Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Multiple sclerosis is a neuroinflammatory demyelinating and neurodegenerative disease of the central nervous system characterized by recurrent and progressive demyelination/remyelination cycles, neuroinflammation, oligodendrocyte loss, demyelination, and axonal degeneration. Cyclic phosphatidic acid (cPA) is a natural phospholipid mediator with a unique cyclic phosphate ring structure at the sn-2 and sn-3 positions of the glycerol backbone. We reported earlier that cPA elicits a neurotrophin-like action and protects hippocampal neurons from ischemia-induced delayed neuronal death. We designed, chemically synthesized, and metabolically stabilized derivatives of cPA: 2-carba-cPA (2ccPA), a synthesized compound in which one of the phosphate oxygen molecules is replaced with a methylene group at the sn-2 position. In the present study, we investigated whether 2ccPA exerts protective effects in oligodendrocytes and suppresses pathology in the two most common mouse models of multiple sclerosis. METHODS: To evaluate whether 2ccPA has potential beneficial effects on the pathology of multiple sclerosis, we investigated the effects of 2ccPA on oligodendrocyte cell death in vitro and administrated 2ccPA to mouse models of experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced demyelination. RESULTS: -induced increase in the Bax/Bcl-2 protein expression ratio and phosphorylation levels of p38MAPK and JNK protein. 2ccPA treatment reduced cuprizone-induced demyelination, microglial activation, NLRP3 inflammasome, and motor dysfunction. Furthermore, 2ccPA treatment reduced autoreactive T cells and macrophages, spinal cord injury, and pathological scores in EAE, the autoimmune multiple sclerosis mouse model. CONCLUSIONS: We demonstrated that 2ccPA protected oligodendrocytes via suppression of the mitochondrial apoptosis pathway. Also, we found beneficial effects of 2ccPA in the multiperiod of cuprizone-induced demyelination and the pathology of EAE. These data indicate that 2ccPA may be a promising compound for the development of new drugs to treat demyelinating disease and ameliorate the symptoms of multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190
Matsushima, G. K., & Morell, P. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00385.x · Cited by 984 · cited 2×
“The cuprizone model is characterized by the apoptotic death of mature oligodendrocytes [7] and is accompanied by neuroinflammation and motor dysfunction [9].”
BackgroundThe cuprizone animal model: new insights into an old story
Kipp, M., Clarner, T., Dang, J., Copray, S., & Beyer, C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0591-3 · Cited by 481 · cited 1×
“These pathological features are also characteristics of lesion formation in human multiple sclerosis [10].”
BackgroundSteinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Mitochondrial defects in acute multiple sclerosis lesions
Mahad, D., Ziabreva, I., Lassmann, H., & Turnbull, D. (2008) · Brain · doi:10.1093/brain/awn105 · Cited by 406
The cuprizone model for demyelination
Torkildsen, Ø., Brunborg, L. A., Myhr, K.-M., & Bø, L. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01036.x · Cited by 346
Jha, S., Srivastava, S. Y., Brickey, W. J., Iocca, H., Toews, A., Morrison, J. P., Chen, V. S., Gris, D., Matsushima, G. K., & Ting, J. P.-Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4088-10.2010 · Cited by 310 · cited 4×
“IL-1β is a pivotal mediator in the neuroinflammatory response [9] and promotes leukocyte infiltration by inducing the expression of many cytokines, chemokines, and adhesion molecules.”
BackgroundMethodInfluentialAlfonso-Loeches, S., Ureña-Peralta, J. R., Morillo-Bargues, M. J., Oliver-De La Cruz, J., & Guerri, C. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00216 · Cited by 265
Rasmussen, S., Wang, Y., Kivisäkk, P., Bronson, R. T., Meyer, M., Imitola, J., & Khoury, S. J. (2007) · Brain · doi:10.1093/brain/awm219 · Cited by 154
Cited by
Microglial NLRP3 inflammasome activation in multiple sclerosis
(2020) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2019.08.007 · Cited by 83
Motor Behavioral Deficits in the Cuprizone Model: Validity of the Rotarod Test Paradigm
Lubrich, C., Giesler, P., & Kipp, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911342 · Cited by 77
Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model
Leo, H., & Kipp, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416093 · Cited by 46
Metadata
- Authors
- Yamamoto, S., Yamashina, K., Ishikawa, M., Gotoh, M., Yagishita, S., Iwasa, K., Maruyama, K., Murakami-Murofushi, K., & Yoshikawa, K.
- Venue
- Journal of Neuroinflammation
- Published
- 2017-07-21
- Volume
- 14
- Issue
- 1
- Pages
- 142-142
- ISSN
- 1742-2094 (ISSN-L)
- OpenAlex
- W2738045881
- Cited by
- 48
- References
- 13
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease. https://app.cochat.ai/papers/10.1186/s12974-017-0923-5
- The paper
- Yamamoto, S., Yamashina, K., Ishikawa, M., Gotoh, M., Yagishita, S., Iwasa, K., Maruyama, K., Murakami-Murofushi, K., & Yoshikawa, K. (2017). Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-017-0923-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.